Tri­fec­ta of in­com­ing mi­graine meds must be cheap­er than trip­tans to be cost-ef­fec­tive — ICER

For mi­graine suf­fer­ers who ben­e­fit from trip­tans — ig­nore the new crop of in­com­ing acute mi­graine med­ica­tions — be­cause your ex­ist­ing gener­ic med­i­cines are more ef­fec­tive and will like­ly be cheap­er, a draft re­port by cost-ef­fec­tive­ness watch­dog ICER sug­gest­ed on Thurs­day.

This year, the ap­proval of a raft of in­jectable mi­graine treat­ments from Te­va, Eli Lil­ly and part­ners Am­gen and No­var­tis ush­ered in a new era of mi­graine pre­ven­tion. Mi­graine is the third most preva­lent ill­ness in the world, af­fect­ing about 39 mil­lion in the Unit­ed States, and costs bil­lions in health­care costs and lost pro­duc­tiv­i­ty. The mar­ket for mi­graine ther­a­pies is ex­pect­ed to hit $8.7 bil­lion by 2026, Glob­al­Da­ta es­ti­mates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER